Renaissance Technologies LLC decreased its holdings in Kura Oncology, Inc. (NASDAQ:KURA – Free Report) by 49.5% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 121,200 shares of the company’s stock after selling 119,000 shares during the quarter. Renaissance Technologies LLC owned about 0.16% of Kura Oncology worth $2,496,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in KURA. BVF Inc. IL raised its stake in Kura Oncology by 9.5% in the fourth quarter. BVF Inc. IL now owns 7,373,228 shares of the company’s stock valued at $106,027,000 after buying an additional 642,245 shares during the last quarter. Vanguard Group Inc. grew its position in Kura Oncology by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 4,065,903 shares of the company’s stock worth $86,726,000 after purchasing an additional 28,212 shares during the last quarter. Avoro Capital Advisors LLC increased its stake in Kura Oncology by 29.2% during the 1st quarter. Avoro Capital Advisors LLC now owns 3,850,000 shares of the company’s stock valued at $82,120,000 after purchasing an additional 870,000 shares in the last quarter. Artal Group S.A. raised its holdings in shares of Kura Oncology by 8.6% in the first quarter. Artal Group S.A. now owns 1,919,884 shares of the company’s stock worth $40,951,000 after buying an additional 151,828 shares during the last quarter. Finally, Assenagon Asset Management S.A. lifted its stake in shares of Kura Oncology by 50.1% during the second quarter. Assenagon Asset Management S.A. now owns 1,731,577 shares of the company’s stock worth $35,653,000 after buying an additional 577,732 shares during the period.
Kura Oncology Trading Down 1.7 %
KURA stock opened at $19.21 on Wednesday. Kura Oncology, Inc. has a 12-month low of $7.41 and a 12-month high of $24.17. The business’s 50-day moving average is $20.00 and its 200 day moving average is $20.49. The company has a current ratio of 14.94, a quick ratio of 14.94 and a debt-to-equity ratio of 0.02. The stock has a market cap of $1.46 billion, a price-to-earnings ratio of -8.85 and a beta of 0.84.
Wall Street Analysts Forecast Growth
KURA has been the subject of a number of research analyst reports. HC Wainwright restated a “buy” rating and issued a $32.00 target price on shares of Kura Oncology in a research note on Monday, August 12th. JMP Securities reiterated a “market outperform” rating and issued a $32.00 target price on shares of Kura Oncology in a research report on Monday, August 12th. Wedbush reissued an “outperform” rating and set a $37.00 price target on shares of Kura Oncology in a research report on Friday, August 9th. Stifel Nicolaus cut their price objective on shares of Kura Oncology from $28.00 to $26.00 and set a “buy” rating on the stock in a research note on Friday, August 9th. Finally, StockNews.com downgraded shares of Kura Oncology from a “hold” rating to a “sell” rating in a research report on Thursday, August 22nd. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company. According to data from MarketBeat, Kura Oncology has a consensus rating of “Moderate Buy” and an average price target of $30.60.
View Our Latest Stock Report on Kura Oncology
Kura Oncology Profile
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.
Featured Articles
- Five stocks we like better than Kura Oncology
- Stock Market Sectors: What Are They and How Many Are There?
- Why Lennar Stock Could Be the Best Play in the Housing Market
- How to Effectively Use the MarketBeat Ratings Screener
- 2 Energy Stocks Fueling the AI Datacenter Boom
- How to Calculate Inflation Rate
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Want to see what other hedge funds are holding KURA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kura Oncology, Inc. (NASDAQ:KURA – Free Report).
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.